AACR 2026: Multiple China-Developed First-in-Class (FIC) Therapeutics Make Global Debut

The American Association for Cancer Research (AACR) Annual Meeting is one of the largest and most influential academic events in the field of oncology worldwide. The 2026 AACR Annual Meeting will be held from April 17 to 22, 2026, in San Diego, USA.

Currently, the AACR Annual Meeting has become an important platform for innovative pharmaceutical companies in China to showcase their latest research achievements. At this year's conference, there wereMore Than 100 Chinese Pharmaceutical Companies Showcase Nearly 400 Research Achievements, covering cutting-edge sectors such as ADC, bispecific antibodies, multispecific antibodies, mRNA, and AI-driven drug discovery.

BiocytogenWill present 36 latest research achievements in poster format, including various drug modalities such as fully human monoclonal antibodies, bispecific/multi-specific antibodies, monoclonal and bispecific antibody-drug conjugates (ADC), nanobodies (VHH), and TCR molecules, along with advancements in 12 preclinical animal models and pharmacological efficacy studies.

Leads BiolabsWill Announce Latest Research Findings of Two Preclinical Pipelines at the Conference, Demonstrating the Technical Strength of the IO+ADC Synergistic Platform. Specifically: Preclinical Research Data of LBL-054, the World’s First T Cell Engager-Drug Conjugate (TDC), and LBL-061, a Novel EGFR/PD-L1 Bispecific Antibody-Drug Conjugate (ADC).

Orange Sail PharmaceuticalsThree innovative drugs will be showcased at this conference: VBC101 (EGFR/cMET bispecific ADC) in the clinical stage, and VBC229 (DLL3 dual-epitope TCE-TOPO1i fusion molecule) and VTS208 (CD3/CLDN18.2/CDH17 trispecific TCE), both in the preclinical stage.

Junshi BiosciencesFirst Disclosure of Phase I First-in-Human (FIH) Clinical Study and Preclinical Study Data for JS212 (EGFR/HER3 Bispecific ADC) in Advanced Solid Tumors, Phase II Clinical Study Data for JS207 (PD-1/VEGF Bispecific Antibody) in Combination with Chemotherapy for Metastatic Colorectal Cancer (CRC), and JS207 (CTLA-4 Monoclonal Antibody) in Combination with JS007 for Advanced Hepatocellular Carcinoma (HCC).

Everest MedicinesEverest Medicines will announce the first-in-human trial data of its self-developed mRNA personalized cancer therapeutic vaccine, EVM16. This drug is a novel mRNA personalized cancer therapeutic vaccine independently developed by Everest Medicines and driven by AI algorithms to identify neoantigens in tumors. Based on the unique mutations of tumor cells in each patient, the self-developed and self-iterative EVER-NEO-1 "Miaosuan" Neoantigen AI Algorithm System is used to identify neoantigens with high immunogenicity and design an mRNA therapeutic vaccine encoding dozens of neoantigens. Preclinical studies have shown that it can effectively activate neoantigen-specific T cells, significantly inhibit tumor growth, and has good safety and tolerability.

AbogenThe mRNA lipid nanoparticle ABO2203 targeting CD19/CD3 TCE has been successfully selected for an oral presentation at AACR, where the first-in-human clinical trial results of ABO2203 will be disclosed, evaluating the safety, tolerability, and preliminary efficacy of ABO2203 in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

Insilico MedicineFour Preclinical Research Achievements from Self-Developed Tumor Pipelines Selected for Poster Presentation at the Conference, Including Novel Oral Pan-KRAS Inhibitor ISM6166, AI-Assisted Innovative CBLB Inhibitor ISM3830, AI-Driven CDK4 Selective Inhibitor ISM6210, and MTA-Cooperative PRMT5 Inhibitor ISM1745.

Source: Compiled from public information

Editor-in-Chief| Little Moon Stone

Cooperation, Contribution | HorseTeacher18323856316 (Same as WeChat)

 Read the original text, it isPopular Articles